Search

everythinglearnresearchcommunity

for

Search:↓

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

Hair loss in androgenic alopecia patients is linked to changes in certain genes that control cell growth and death.

The document concludes that current treatments for androgenic alopecia are not fully effective, but new therapies like botulinum toxin and PRP show promise, and future gene therapy could be beneficial.

Women with hair thinning have disrupted steroid hormone levels, but this doesn't often show as other health issues. More research is needed on hormone balance in this condition.

Male-pattern hair loss is normal, often involves hormone effects on hair follicles, and can be treated with medication or surgery, but new treatments are being researched.

Iron supplements may reverse premature graying in iron-deficient individuals; ingrown nails are common in diabetics with certain risk factors; topical finasteride may reduce scalp DHT as effectively as oral finasteride; monilethrix treatment is challenging but some medications can help.

Minoxidil and finasteride are effective long-term treatments for male hair loss.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Testosterone increases muscle mass regardless of DHT conversion blocking.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

Traditional Indian remedies are used for hair health, but more scientific evidence is needed to prove their safety and effectiveness.

Family history affects onset and severity of androgenic alopecia, but treatment success depends more on therapy duration.

Prostate cancer risk is not linked to blood testosterone levels.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Male pattern baldness may be linked to prostate cancer risk.

Hair transplantation is a treatment for hair loss mainly caused by genetics, with various techniques and potential complications, and results visible after 8-12 months.

After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.

The conclusion suggests a new treatment for infantile hemangiomas and a potential target for hair loss treatment.

Free fatty acids may increase androgen production, potentially contributing to polycystic ovary syndrome.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

Parthenolide promotes hair growth in mice and may influence pathways related to male pattern baldness.

Hair loss is mainly caused by a testosterone byproduct, and hair restoration surgery uses hair from the back and sides of the scalp.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

White wax and its policosanol boost hair growth better than finasteride.

Minoxidil and finasteride are key treatments for hair loss.

Anti-androgen drugs can treat conditions like prostate cancer and male pattern baldness by blocking effects of testosterone and DHT.